癌症中microRNAs和表观遗传之间的相互调控作用

doi:10.13560/j.cnki.biotech.bull.1985.2019-0960

摘要/Abstract

摘要： 与基因DNA序列发生变化一样,表观遗传畸变也是决定人类癌症发生的关键因素之一。最近,越来越多的研究发现,microRNAs 参与调控表观遗传,并与表观遗传形成一个相互作用的复杂调控网络。已有研究表明,表观遗传修饰,如DAN甲基化和组蛋白修饰,能够影响microRNAs的表达;反过来,microRNAs也可通过靶向表观遗传的关键酶来调控表观遗传。对microRNAs和表观遗传之间的相互作用调控回路进行综述,重点阐明在人类癌症中表观遗传如何影响microRNAs表达及microRNAs又是如何控制表观遗传的,并对表观遗传和microRNAs相互调控的临床转化意义进行讨论。

关键词: microRNAs, 表观遗传, DNA甲基化, 组蛋白修饰, 癌症

Abstract: Along with the crucial role of genetic abnormalities,epigenetic aberration is emerging as one key relevant player in human cancers. Nowadays,accumulating evidences suggest that microRNAs（miRNAs）,as an important regulator in epigenetics,enter the epigenetic field. miRNAs and epigenetic machinery are the interactional players in the regulation of gene expression. Indeed,compelling evidence has indicated that epigenetic modifications,such as DNA methylation or histone acetylation,can affect miRNAs expression,and to be potentially responsible for the aberrant miRNA observed in cancer,in turn,miRNAs also can control the epigenetic machinery through directly targeting its enzymatic components. This review will describe the mutual regulation of miRNAs and epigenetics,and particularly focus on illuminating how epigenetics can affect the miRNAs expression,as well as how miRNAs can control epigenetics in human cancer. Finally,the review will discuss the translational clinical implications of the epigenetics/miRNA mutual regulation.

Key words: microRNAs, epigenetics, DNA methylation, histone modification, cancer

唐德平, 姚慧慧, 唐金舟, 毛爱红. 癌症中microRNAs和表观遗传之间的相互调控作用[J]. 生物技术通报, 2020, 36(8): 194-200.

TANG De-ping, YAO Hui-hui, TANG Jin-zhou, MAO Ai-hong. Mutual Regulation of microRNAs and Epigenetics in Human Cancers[J]. Biotechnology Bulletin, 2020, 36(8): 194-200.

参考文献

[1] Esteller M.Cancer epigenomics:DNA methylomes and histone-modification maps[J]. Nature Reviews Genetics, 2007, 8(4):286-298.
[2] Pan Y, Liu G, Zhou F, et al.DNA methylation profiles in cancer diagnosis and therapeutics[J]. Clinical and Experimental Medicine, 2018, 18(1):1-14.
[3] Liang G, Weisenberger DJ.DNA methylation aberrancies as a guide for surveillance and treatment of human cancers[J]. Epigenetics, 2017, 12(6):416-432.
[4] Audia JE, Campbell RM.Histone modifications and cancer[J]. Cold Spring Harbor Perspectives in Biology, 2016, 8(4):a019521.
[5] Choudhary C, Kumar C, Gnad F, et al.Lysine acetylation targets protein complexes and co-regulates major cellular functions[J]. Science, 2009, 325(5942):834-840.
[6] McCabe MT, Mohammad HP, Barbash O, et al. Targeting histone methylation in cancer[J]. Cancer J, 2017, 23(5):292-301.
[7] Biswas S, Rao CM.Epigenetics in cancer:Fundamentals and beyond[J]. Pharmacology & Therapeutics, 2017, 173(5):118-134.
[8] Romania P, Bertaina A, Bracaglia G, et al.Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives[J]. Int J Mol Sci, 2012, 13(12):16554-16579.
[9] Van Roosbroeck K, Calin GA.Cancer hallmarks and microRNAs:The therapeutic connection[J]. Advances in Cancer Research, 2017, 135(8):119-149.
[10] Iorio MV, Piovan C, Croce CM.Interplay between microRNAs and the epigenetic machinery:an intricate network[J]. Biochimica et Biophysica Acta, 2010, 1799(10-12):694-701.
[11] Datta J, Kutay H, Nasser MW, et al.Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis[J]. Cancer Research, 2008, 68(13):5049-5058.
[12] Lujambio A, Ropero S, Ballestar E, et al.Genetic unmasking of an epigenetically silenced microRNA in human cancer cells[J]. Cancer Research, 2007, 67(4):1424-1429.
[13] Wang S, Wu W, Claret FX.Mutual regulation of microRNAs and DNA methylation in human cancers[J]. Epigenetics, 2017, 12(3):187-197.
[14] Brueckner B, Stresemann C, Kuner R, et al.The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function[J]. Cancer Research, 2007, 67(4):1419-1423.
[15] Hirata Y, Murai N, Yanaihara N, et al.MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma[J]. BMC Cancer, 2014, 14(1):799-808.
[16] Scott GK, Mattie MD, Berger CE, et al.Rapid alteration of microRNA levels by histone deacetylase inhibition[J]. Cancer Research, 2006, 66(3):1277-1281.
[17] Vrba L, Jensen TJ, Garbe JC, et al.Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells[J]. PLoS One, 2010, 5(1):e8697.
[18] Baer C, Claus R, Plass C.Genome-wide epigenetic regulation of miRNAs in cancer[J]. Cancer research, 2013, 73(2):473-477.
[19] Kwon JJ, Factora TD, Dey S et al. A systematic review of mir-29 in cancer[J]. Molecular Therapy Oncolytics, 2019, 12(3):173-194.
[20] Fabbri M, Garzon R, Cimmino A, et al.MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B[J]. PNAS, 2007, 104(40):15805-15810.
[21] Garzon R, Liu S, Fabbri M, et al.MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1[J]. Blood, 2009, 113(25):6411-6418.
[22] Xu Q, Jiang Y, Yin Y, et al.A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1[J]. Journal of Molecular Cell Biology, 2013, 5(1):3-13.
[23] Xiang Y, Ma N, Wang D, et al.MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly:a novel epigenetic therapy independent of decitabine[J]. Oncogene, 2014, 33(3):378-386.
[24] Zagorac S, Alcala S, Fernandez Bayon G, et al.DNMT1 inhibition reprograms pancreatic cancer stem cells via upregulation of the mir-17-92 cluster[J]. Cancer Research, 2016, 76(15):4546-4558.
[25] Wang L, Zhang X, Jia LT, et al.c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma[J]. Hepatology, 2014, 59(5):1850-1863.
[26] Godlewski J, Nowicki MO, Bronisz A, et al.Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal[J]. Cancer Research, 2008, 68(22):9125-9130.
[27] Wang H, Garzon R, Sun H, et al.NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma[J]. Cancer Cell, 2008, 14(5):369-381.
[28] Tchio Mantho CI, Harbuzariu A, Gonzalez-Perez RR.Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer[J]. World Journal of Clinical Oncology, 2017, 8(3):178-189.
[29] Noonan EJ, Place RF, Pookot D, et al.miR-449a targets HDAC-1 and induces growth arrest in prostate cancer[J]. Oncogene, 2009, 28(14):1714-1724.
[30] Sandhu SK, Volinia S, Costinean S, et al.miR-155 targets histone deacetylase 4(HDAC4)and impairs transcriptional activity of B-cell lymphoma 6(BCL6)in the Emu-miR-155 transgenic mouse model[J]. PNAS, 2012, 109(49):20047-20052.
[31] Xiao Q, Huang L, Zhang Z, et al.Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4[J]. Oncology Research, 2017, 25(2):267-275.
[32] Luo J, Chen P, Xie W, et al.MicroRNA-138 inhibits cell proliferation in hepatocellular carcinoma by targeting Sirt1[J]. Oncology Reports, 2017, 38(2):1067-1074.
[33] Rastgoo N, Abdi J, Hou J, et al.Role of epigenetics-microRNA axis in drug resistance of multiple myeloma[J]. Journal of Hematology & Oncology, 2017, 10(1):121-130.
[34] Amodio N, Rossi M, Raimondi L, et al.miR-29s:a family of epi-miRNAs with therapeutic implications in hematologic malignancies[J]. Oncotarget, 2015, 6(15):12837-12861.